Vimarsana
Biggest News Aggregation in the World

Page 18 - Gena Wang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gena Wang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gena Wang Today - Breaking & Trending Today

Sangamo Therapeutics, inc (SGMO) Q3 2021 Earnings Call Transcript - Vimarsana News

Sangamo Therapeutics, inc (SGMO) Q3 2021 Earnings Call Transcript

SGMO earnings call for the period ending October 3, 2021.

Source: fool.com
Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Transcript - Vimarsana News

Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Transcript

ALNY earnings call for the period ending September 30, 2021.

Source: fool.com
Cellectis SA (CLLS) Q2 2021 Earnings Call Transcript - Vimarsana News

Cellectis SA (CLLS) Q2 2021 Earnings Call Transcript

CLLS earnings call for the period ending August 6, 2021.

Source: fool.com
Alnylam Pharmaceuticals, inc (ALNY) Q2 2021 Earnings Call Transcript - Vimarsana News

Alnylam Pharmaceuticals, inc (ALNY) Q2 2021 Earnings Call Transcript

Operator Ladies and gentlemen, thank you for standing by, and welcome to the Alnylam Pharmaceuticals Q2 2021 Earnings Call. [Operator Instructions] I would now like to turn the call over to your host, Christine Lindenboom. You may begin. Christine Regan Lindenboom -- Senior Vice President, Investor Relations and Corporate Communications Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are John Maraganore, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Akshay Vaishnaw, Pr...

Source: fool.com
Analysts See Vertex as Buying Opportunity as Stock Plunges - Vimarsana News

Analysts See Vertex as Buying Opportunity as Stock Plunges

Vertex nixes its effort to develop a therapy for a rare genetic disorder that affects the lungs and liver, but analysts see a drop in the stock price as a buying opportunity.